{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/62d20dbcffef490011c8df4b/6417cea8ed587b0011baa100?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"32. Oligometastatic Colorectal Cancer - Is it curable?","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/62d20dbcffef490011c8df4b/1687475593400-d561eb4bb7da56b115ffe28bfc3aade1.jpeg?height=200","description":"<p>Today, our intrepid trio once more plunge down 20,000 leagues, exploring the confusing depths, hoping to answer one question: is there any evidence to support using systemic therapy in patients with potentially resectable oligometastatic colorectal cancer? The answer will take them to many dark, barely-explored corners of their profession and will raise more questions than answers. Following in the forebears of many explorers, it may drive them completely mad, or at least madder than they already are. But, to paraphrase Captain Nemo of the <em>Nautilus: </em>\"the Earth does not want new continents, but new evidence for patients with resectable metastatic colorectal cancer.\"</p><p><br></p><p>Links to studies discussed in this episode (subscription may be required):</p><p><strong>OLIVIA: </strong><a href=\"https://www.annalsofoncology.org/article/S0923-7534(19)31451-6/fulltext#ec0035\" rel=\"noopener noreferrer\" target=\"_blank\">https://www.annalsofoncology.org/article/S0923-7534(19)31451-6/fulltext#ec0035</a></p><p><strong>Falcone et al.: </strong><a href=\"https://ascopubs.org/doi/10.1200/JCO.2006.09.0928?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub%20%200pubmed\" rel=\"noopener noreferrer\" target=\"_blank\">https://ascopubs.org/doi/10.1200/JCO.2006.09.0928?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub%20%200pubmed</a></p><p><strong>TRIBE: </strong><a href=\"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00122- /fulltext#:~:text=TRIBE%20was%20an%20open%2Dlabel,were%20recruited%20from%2034%20Italian\" rel=\"noopener noreferrer\" target=\"_blank\">https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00122- /fulltext#:~:text=TRIBE%20was%20an%20open%2Dlabel,were%20recruited%20from%2034%20Italian</a></p><p><br></p><p>For more episodes, resources and blog posts, visit<strong> </strong><a href=\"www.inquisitiveonc.com\" rel=\"noopener noreferrer\" target=\"_blank\"><strong>www.inquisitiveonc.com</strong></a></p><p>Find us on Twitter <strong>@InquisitiveOnc!</strong></p><p>If you want us to look at a specific trial or subject, email us at<strong> </strong><a href=\"mailto:inquisitiveonc@gmail.com\" rel=\"noopener noreferrer\" target=\"_blank\"><strong>inquisitiveonc@gmail.com</strong></a></p><p><br></p><p>Art courtesy of Taryn Silver</p><p>Music courtesy of:</p><p>- Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/</p><p>- SoulProdMusic: https://pixabay.com/users/soulprodmusic-30064790/</p><p><br></p><p><strong>Disclaimer:</strong> This podcast is for educational purposes only. If you are unwell, seek medical advice.</p>","author_name":"Michael Fernando and Josh Hurwitz"}